Key result
HCM is linked to an ~115% higher risk of bradyarrhythmias versus matched controls.
Why the study?
The relationship between hypertrophic cardiomyopathy and bradyarrhythmia, as well as the subsequent need for permanent pacemaker implantation, remains unclear.
Does hypertrophic cardiomyopathy increase the risk of bradyarrhythmia and permanent pacemaker implantation compared to matched controls without the disease?
Cohort (n=15,266)
Yes
Does hypertrophic cardiomyopathy increase the risk of bradyarrhythmia and permanent pacemaker implantation compared to matched controls without the disease?
Answers are grounded in this paper and cite their sources.
Hypertrophic cardiomyopathy is independently associated with a significantly increased risk of developing bradyarrhythmia and requiring permanent pacemaker implantation, particularly in patients with concurrent atrial fibrillation or heart failure.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is associated with various arrhythmias, including bradyarrhythmia. The relationship between HCM and bradyarrhythmia, and subsequent need for permanent pacemaker (PPM) implantation, remains unclear. This study aimed to evaluate the risk of bradyarrhythmia and PPM implantation in HCM patients. METHODS: This retrospective, population-based cohort study identified patients with newly diagnosed HCM from 2012 to 2017 in Taiwan's National Health Insurance Research Database. Patients with prior bradyarrhythmia or PPM implantation were excluded. A control cohort was selected by matching patients without HCM to the study cohort by age and gender in a 1:1 ratio. The primary and secondary outcomes were the occurrence of bradyarrhythmia and PPM implantation, respectively. A multivariate Cox proportional hazards regression model was used to evaluate the hazard ratios (HR) for the outcomes. RESULTS: A total of 15 266 patients with a mean age of 63.8 ± 14.5 years constituted the HCM (n = 7633) and control (n = 7633) cohorts. During a follow-up period of 4.05 ± 2.03 years, HCM was associated with higher risks of bradyarrhythmia (adjusted HR: 2.15, p < 0.001) and PPM implantation (adjusted HR: 6.58, p < 0.001). In patients with HCM, the presence of AF increased the risks of both bradyarrhythmia (adjusted HR: 1.61, p < 0.001) and PPM implantation (adjusted HR: 2.12, p < 0.001), while HF increased the risks of PPM implantation (adjusted HR: 1.61, p < 0.001). CONCLUSIONS: Patients with HCM had higher risks of bradyarrhythmia and PPM implantation. Patients with HCM should be carefully monitored for AF and HF, which might increase the risks of future PPM implantation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (HCM) (n=15,266). Hypertrophic cardiomyopathy vs. Matched patients without hypertrophic cardiomyopathy was evaluated on Occurrence of bradyarrhythmia (composite of sick sinus syndrome, atrioventricular block, and junctional bradycardia) (HR 2.15, 95% CI 1.73-2.67, p=<0.001). Hypertrophic cardiomyopathy was associated with a significantly higher risk of bradyarrhythmia (HR 2.15) and permanent pacemaker implantation (HR 6.58) compared to matched controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: